Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the ...
OHSU one of 20 sites hosting the clinical trial for the amyloidosis therapy. Masri, who is overseeing the trial in Oregon, told The Lund Report that finding a way to deliver gene therapy directly to ...